• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

IMGN853在卵巢癌联合治疗中诱导自噬性细胞死亡。

IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer.

作者信息

Chelariu-Raicu Anca, Vu Thanh Chung, Umamaheswaran Sujanitha, Stur Elaine, Hanjra Pahul, Han Yunah, Hu Min, Lin Jerome, Lawson Barrett C, Liu Jinsong, Sood Anil K, Wen Yunfei

机构信息

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.

出版信息

Cancer Res Commun. 2025 Mar 1;5(3):512-526. doi: 10.1158/2767-9764.CRC-24-0215.

DOI:10.1158/2767-9764.CRC-24-0215
PMID:40029935
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11951858/
Abstract

FOLR1 is heterogeneously overexpressed in epithelial ovarian cancer. We examined the combined effects of the anti-FOLR1 antibody-drug conjugate (IMGN853) with other drugs, including topotecan, anti-VEGF-A antibody, and olaparib. These findings could contribute to the continued development of IMGN853 in the treatment of ovarian cancer.

摘要

叶酸受体1（FOLR1）在上皮性卵巢癌中呈异质性过表达。我们研究了抗FOLR1抗体药物偶联物（IMGN853）与其他药物（包括拓扑替康、抗血管内皮生长因子A（VEGF-A）抗体和奥拉帕利）联合使用的效果。这些发现可能有助于IMGN853在卵巢癌治疗中的持续研发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd5/11951858/8accf86986e9/crc-24-0215_f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd5/11951858/8accf86986e9/crc-24-0215_f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd5/11951858/8accf86986e9/crc-24-0215_f6.jpg

相似文献

1
IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer.IMGN853在卵巢癌联合治疗中诱导自噬性细胞死亡。
Cancer Res Commun. 2025 Mar 1;5(3):512-526. doi: 10.1158/2767-9764.CRC-24-0215.
2
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.米拉维单抗索拉坦辛（IMGN853），一种靶向叶酸受体α的抗体药物偶联物，可增强卵巢癌模型中标准治疗药物的活性。
Neoplasia. 2016 Dec;18(12):775-784. doi: 10.1016/j.neo.2016.11.002. Epub 2016 Nov 25.
3
IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.IMGN853，一种叶酸受体-α（FRα）靶向抗体药物偶联物，对 FRα 表达的肿瘤表现出强大的靶向抗肿瘤活性。
Mol Cancer Ther. 2015 Jul;14(7):1605-13. doi: 10.1158/1535-7163.MCT-14-1095. Epub 2015 Apr 22.
4
and Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers.靶向叶酸受体-α的抗体药物偶联物 IMGN853 联合 DM4 治疗生物侵袭性子宫内膜癌的活性。
Mol Cancer Ther. 2018 May;17(5):1003-1011. doi: 10.1158/1535-7163.MCT-17-0930. Epub 2018 Feb 13.
5
Folate Receptor α-Targeted Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer.叶酸受体 α 靶向 Zr-M9346A 免疫 PET 显像指导 Mirvetuximab Soravtansine 治疗三阴性乳腺癌的研究
Mol Pharm. 2019 Sep 3;16(9):3996-4006. doi: 10.1021/acs.molpharmaceut.9b00653. Epub 2019 Aug 16.
6
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.Mirvetuximab Soravtansine（IMGN853），一种靶向叶酸受体α的抗体药物偶联物，在铂耐药卵巢癌、输卵管癌或原发性腹膜癌中的安全性和活性：一项I期扩展研究。
J Clin Oncol. 2017 Apr 1;35(10):1112-1118. doi: 10.1200/JCO.2016.69.9538. Epub 2016 Dec 28.
7
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.mirvetuximab soravtansine（IMGN853），一种靶向叶酸受体α的抗体药物偶联物，在实体瘤患者中的1期剂量递增研究。
Cancer. 2017 Aug 15;123(16):3080-3087. doi: 10.1002/cncr.30736. Epub 2017 Apr 25.
8
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.恩替诺特，一种选择性的 HDAC1/2 抑制剂，增强了奥拉帕利在同源重组修复有效的卵巢癌中的疗效。
Gynecol Oncol. 2021 Jul;162(1):163-172. doi: 10.1016/j.ygyno.2021.04.015. Epub 2021 Apr 16.
9
Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.厄洛替尼与PARP抑制剂联合使用可抑制A2780肿瘤异种移植瘤的生长，原因是自噬增加。
Drug Des Devel Ther. 2015 Jun 22;9:3183-90. doi: 10.2147/DDDT.S82035. eCollection 2015.
10
Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate.用抗叶酸受体1（FOLR1）抗体药物偶联物治疗晚期卵巢癌的患者预后
Gynecol Oncol. 2025 Apr;195:173-179. doi: 10.1016/j.ygyno.2025.03.023. Epub 2025 Mar 22.

引用本文的文献

1
Siramesine induced cell death of glioblastoma through inactivating the STAT3-MGMT signaling pathway.西拉莫辛通过使STAT3-MGMT信号通路失活诱导胶质母细胞瘤细胞死亡。
J Transl Med. 2025 Jul 10;23(1):780. doi: 10.1186/s12967-025-06693-y.
2
Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment.探索抗体药物偶联物在卵巢癌治疗中的治疗用途及疗效。
Oncogene. 2025 May 27. doi: 10.1038/s41388-025-03448-3.

本文引用的文献

1
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.珐瑯质蛋白相关细胞黏附分子阳性、铂类耐药卵巢癌中的 Mirvetuximab Soravtansine。
N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169.
2
Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer.针对多倍体巨癌细胞可增强治疗反应，并克服卵巢癌对 PARP 抑制剂的耐药性。
Sci Adv. 2023 Jul 21;9(29):eadf7195. doi: 10.1126/sciadv.adf7195.
3
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.
FDA 批准概要：Mirvetuximab Soravtansine-Gynx 用于 FRα 阳性、铂耐药性卵巢癌。
Clin Cancer Res. 2023 Oct 2;29(19):3835-3840. doi: 10.1158/1078-0432.CCR-23-0991.
4
Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L.通过靶向 CD5L 克服抗 VEGF 治疗的适应性耐药。
Nat Commun. 2023 Apr 26;14(1):2407. doi: 10.1038/s41467-023-36910-5.
5
Integrating antibody drug conjugates in the management of gynecologic cancers.将抗体药物偶联物整合到妇科癌症的治疗中。
Int J Gynecol Cancer. 2023 Mar 6;33(3):420-429. doi: 10.1136/ijgc-2022-003701.
6
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.高叶酸受体α表达的铂耐药卵巢癌患者中 Mirvetuximab Soravtansine 的疗效和安全性：来自 SORAYA 研究的结果。
J Clin Oncol. 2023 May 1;41(13):2436-2445. doi: 10.1200/JCO.22.01900. Epub 2023 Jan 30.
7
Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes.不同的转录程序将卵巢癌细胞系分为五个主要组织学亚型。
Genome Med. 2021 Sep 1;13(1):140. doi: 10.1186/s13073-021-00952-5.
8
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.III 期随机临床试验：索拉非尼单药治疗与化疗用于铂耐药卵巢癌患者的比较：FORWARD I 研究的主要分析。
Ann Oncol. 2021 Jun;32(6):757-765. doi: 10.1016/j.annonc.2021.02.017. Epub 2021 Mar 2.
9
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.叶酸受体 α（FRα）靶向抗体药物偶联物（ADC）mirvetuximab soravtansine 联合贝伐珠单抗治疗铂耐药卵巢癌的 Ib 期研究。
Gynecol Oncol. 2020 May;157(2):379-385. doi: 10.1016/j.ygyno.2020.01.037. Epub 2020 Feb 18.
10
High-throughput quantitative detection of basal autophagy and autophagic flux using image cytometry.使用图像细胞仪进行高通量定量检测基础自噬和自噬流。
Biotechniques. 2019 Aug;67(2):70-73. doi: 10.2144/btn-2019-0044. Epub 2019 Jun 26.